[痴呆症:从ICD-10到ICD-11的变化. 德语版本] 德语版本] 德语版本]
Frank Jessen1,2, Karl Broich3
1Klinik und Poliklinik für Psychiatrie und Psychotherapie, Medizinische Fakultät, Uniklinik Köln, Kerpener Straße 62, 50937, Köln, Deutschland. frank.jessen@uk-koeln.de.
Der Nervenarzt
|September 24, 2025
概括
疾病和相关健康问题的国际统计分类第11版 (ICD-11) 增强了痴呆症的分类,包括严重程度和症状重点. 然而,它缺乏专家标准和神经退行性疾病的生物标志物集成.
科学领域:
- 神经学 神经学
- 医学分类系统 医学分类系统
- 老年病的医生 老年病的医生
背景情况:
- 疾病与相关健康问题的国际统计分类,第10版 (ICD-10),在分类痴呆症方面存在局限性.
- 了解神经退行性疾病的进步需要更新的分类系统.
研究的目的:
- 评估ICD-11对ICD-10在痴呆症分类方面的概念进步.
- 确定ICD-11关于痴呆症诊断和分类的改进领域.
主要方法:
- 对神经认知障碍的ICD-11和ICD-10分类结构进行比较分析.
- 审查将临床诊断标准和病因生物标志物纳入ICD-11.
主要成果:
- ICD-11引入了严重程度等级,并强调精神/行为症状,以便更精确地编码痴呆症.
- 在ICD-11中,轻度神经认知障碍作为前发性痴呆状态的新类别被列入ICD-11.
- ICD-11没有充分纳入专家为特定痴呆症 (例如,前性痴呆症,勒维体病) 开发的临床标准,也没有提到病因诊断的生物标志物.
结论:
- 与ICD-10相比,ICD-11代表了痴呆症分类的重大概念改进.
- 需要对ICD-11进行进一步的更新,以整合先进的临床标准和生物标志物信息,以便全面诊断和分类痴呆症.
- 鉴于神经退行性疾病研究的快速进展,定期修订ICD-11至关重要.
相关概念视频
Diagnostic and Statistical Manual of Mental Disorders (DSM)
1.1K
The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...
1.1K
Dementia
523
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
523
Intellectual Disability
641
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
641
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Heart Failure IV: Classification and Diagnostic Evaluation
321
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
321
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824


